AMG 199
Alternative Names: AMG-199; MUC17 HLE BiTE®Latest Information Update: 14 Jun 2025
At a glance
- Originator Amgen
- Developer Amgen; BeOne Medicines
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastric cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 08 Aug 2023 Discontinued - Phase-I for Gastric cancer in China (IV) (Amgen pipeline, August 2023)
- 08 Aug 2023 Discontinued - Phase-I for Oesophageal cancer in China (IV) (Amgen pipeline, August 2023)
- 08 Aug 2023 Discontinued - Phase-I for Solid tumours (In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA, Taiwan, Spain, South Korea, Netherlands, Japan, Germany, France, Austria (IV) (Amgen pipeline, August 2023)